MHRA publishes GXP data integrity guide

The Medicines and Healthcare Products Regulatory Agency (MHRA) has published a GXP data integrity guide. GXP encompasses various good practices regulated by the UK MHRA, including the Good Laboratory Practice Monitoring Authority (GLPMA). These are Good Clinical Practice (GCP), Good Distribution Practice (GDP), Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and Good Pharmacovigilance Practice (GPvP). The guidance aims to provide useful information on the core elements of a compliant data governance system across all GXP sectors. Read more “MHRA publishes GXP data integrity guide”

Health Canada releases risk classification guide for drug GMP observations

Health Canada has released a risk classification guide that aims to clarify the manufacturing site inspection process for drug manufacturers. The new guidance for good manufacturing practice (GMP) provides information to ensure a uniform approach that inspectors will use to assign one of three different risk classifications to each noncompliance observation noted during inspections of drug manufacturing facilities. The risk classifications are as follows: critical observation (Risk 1), major observation (Risk 2) or other observation (Risk 3). Read more “Health Canada releases risk classification guide for drug GMP observations”

FDA and EMA to share complete inspection reports

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have signed a new confidentiality commitment, a move that will see increased collaboration in the area of medicine manufacturing site inspections.  The FDA will now share full inspection reports that contain non-public and commercially confidential information with the EMA and European Commission.

Read more “FDA and EMA to share complete inspection reports”

*Compliance Check*: Are you keeping your device CER up to date?

A clinical evaluation report (CER) is a key supporting document in the steps to obtaining a CE mark. Whilst the initial CER is required at the start of the device lifecycle, many manufacturer’s often don’t appreciate that the report is a ‘live’ document and it must be updated periodically.

Read more “*Compliance Check*: Are you keeping your device CER up to date?”

MHRA publishes report on 2016 GMP inspection deficiencies

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has released details of GMP inspection deficiencies from last year.

Overall, the number of MHRA inspections increased by 7% in 2016 compared to 2015. Broken down, this equated to 3 more overseas inspections and 18 more UK inspections.

The report breaks down the most cited deficiencies, rated by numbers of critical, major and other findings.

Read more “MHRA publishes report on 2016 GMP inspection deficiencies”

Importing unlicensed and EMA centrally authorised medicines intended for other EU member states

In the latest blog from the MHRA’s Inspectorate, Mark Birse issues a reminder the about the importation of unlicensed and centrally approved medicines.

Centrally authorised medicines that have an EU marketing authorisations issued by the EMA, cannot be notified to the MHRA for importation as unlicensed medicines.  EMA approval is valid in all Member States so these products should not be considered unlicensed.  Only if importation is from outside the European Economic Area (EEA) for reasons of unavailability of the medicine throughout the EEA could such as an importation take place.

Read more “Importing unlicensed and EMA centrally authorised medicines intended for other EU member states”